2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·6 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·6 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."This is like comparing a supplier of parts to Tesla with Tesla. Algeta owned the medicine – Thor Medical supplies ingredients
·6 t sitten
- ·6 t sittenWhen Biotech goes, they often go up dramatically. 💰💰 There will be FOMO going forward 🔥🔥🔥 Reports this week contribute to sending the price straight up. Can double within next week. Then analysts come crawling with bold analyses.Thor is strictly speaking not biotech, but a supplier to biotech. Thor does not have this type of clinical risk. They are not going to test a medicine on patients. They have built a factory. Their success depends on industrial scaling, production volume and sales contracts. They should be valued as an industrial company, not as a lottery ticket biotech.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·6 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."This is like comparing a supplier of parts to Tesla with Tesla. Algeta owned the medicine – Thor Medical supplies ingredients
- ·6 t sitten
- ·6 t sittenWhen Biotech goes, they often go up dramatically. 💰💰 There will be FOMO going forward 🔥🔥🔥 Reports this week contribute to sending the price straight up. Can double within next week. Then analysts come crawling with bold analyses.Thor is strictly speaking not biotech, but a supplier to biotech. Thor does not have this type of clinical risk. They are not going to test a medicine on patients. They have built a factory. Their success depends on industrial scaling, production volume and sales contracts. They should be valued as an industrial company, not as a lottery ticket biotech.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
2025 H2 -tulosraportti
157 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 | ||
2023 H2 -tulosraportti 28.2.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·6 t sittenInvest tech's technical analysis: Automatic technical analysis. Medium term, 31. Jul 2026 Thor Medical ASA is in a rising trend channel in the medium term. This shows that investors over time have bought at increasingly higher prices to get into the stock and indicates a good development for the company. The stock is moving in a rectangle formation between support at 3.92 kroner and resistance at 5.95 kroner. An established break of one of these levels will signal further direction. The stock has broken up through the resistance at approximately 5.50 kroner. Further upside is thus signaled, and there is now support at 5.50 kroner on reactions back. Volume has previously been high around price tops and low around price bottoms. The volume balance is also positive, which strengthens the trend picture. RSI is above 70 after a good price increase in recent weeks. The stock has strong positive momentum and further upside is indicated.
- ·6 t sittenRead about this and you will potentially understand what Thor could be worth. "The Norwegian biotechnology company Algeta was acquired by the German pharmaceutical giant Bayer in March 2014 for 17.6 billion kroner (2.1 billion euro). The acquisition followed a longer collaboration on the development and commercialization of the prostate cancer medicine Xofigo.Background and DetailsPrice: 336 kroner per share, corresponding to a total transaction value of approx. 17.6 billion kroner.Product: Xofigo (radium-223), a groundbreaking alpha-particle-based medicine against bone metastasis in prostate cancer.Founders: Founded in 1997 by chemist Roy H. Larsen and professor Øyvind S. Bruland.Consequences and Ripple EffectsDelisted: Algeta was delisted from Oslo Børs after the acquisition was formally completed in March 2014.Norwegian environment: Bayer maintained a significant presence in Norway, which has contributed to strengthening the Norwegian professional environment in radiopharmacy afterwards.Development: The sale is considered one of the biggest success stories in Norwegian biotechnology history, even though revenues for Xofigo later faced tougher competition and falling sales a decade later."This is like comparing a supplier of parts to Tesla with Tesla. Algeta owned the medicine – Thor Medical supplies ingredients
- ·6 t sitten
- ·6 t sittenWhen Biotech goes, they often go up dramatically. 💰💰 There will be FOMO going forward 🔥🔥🔥 Reports this week contribute to sending the price straight up. Can double within next week. Then analysts come crawling with bold analyses.Thor is strictly speaking not biotech, but a supplier to biotech. Thor does not have this type of clinical risk. They are not going to test a medicine on patients. They have built a factory. Their success depends on industrial scaling, production volume and sales contracts. They should be valued as an industrial company, not as a lottery ticket biotech.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt